Title : [Achievement of blood lipid target levels with Ezetimibe/Simvastatin in patients with atherosclerosis and/or diabetes mellitus--an Austrian observational study].

Pub. Date : 2009

PMID : 19997842






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 RESULTS: During the follow-up period of 4-12 weeks, LDL-C levels were reduced by a median of 27-31% of baseline values (mean 153.1 +/- 33.5 mg/dl) mainly regardless of previous statin therapy (rosuvastatin, atorvastatin, simvastatin, pravastatin, fluvastatin, and lovastatin) and dosing (pooled median values). Simvastatin component of oligomeric golgi complex 2 Homo sapiens
2 LDL-C reduction correlated proportional with baseline LDL-C values and increased with increasing simvastatin dosage. Simvastatin component of oligomeric golgi complex 2 Homo sapiens
3 CONCLUSIONS: The fixed combination therapy with ezetimibe/simvastatin showed a clinically significant additional lipid-lowering potential as compared with established statin monotherapies and enabled more patients at cardiovascular risk to reach the LDL-C target level of <100 mg/dl. Simvastatin component of oligomeric golgi complex 2 Homo sapiens